Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Tonix Pharmaceuticals files $500M mixed securities shelf  17:18
04/01/21
04/01
17:18
04/01/21
17:18
TNXP

Tonix Pharmaceuticals

$1.22 /

-0.06 (-4.71%)

 
ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.22 /

-0.06 (-4.71%)

TNXP Tonix Pharmaceuticals
$1.22 /

-0.06 (-4.71%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.22 /

-0.06 (-4.71%)

TNXP Tonix Pharmaceuticals
$1.22 /

-0.06 (-4.71%)

Hot Stocks
Tonix expects to be in position to initiate Phase 2 study in MDD in Q4 » 14:34
03/22/21
03/22
14:34
03/22/21
14:34
TNXP

Tonix Pharmaceuticals

$1.39 /

-0.055 (-3.82%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced that it has received the official minutes from a Type B pre-investigational new drug, or IND, meeting with the U.S. Food and Drug Administration on its development plan for TNX-601 CR tablet for the treatment of major depressive disorder, or MDD. Tonix's TNX-601 CR is a novel oral formulation which is being developed as a potential treatment for MDD, posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use. "Tianeptine sodium immediate release has been available in Europe and many countries in Asia and Latin America for the treatment of depression for more than three decades, first marketed in France in 1989," the company noted. Based on the official minutes, Tonix expects to submit the IND to conduct a human abuse potential study and meet with FDA's controlled substances staff to reach agreement on the details of the abuse potential study. Pending the results of the human abuse potential study and the results of ongoing nonclinical toxicology studies, Tonix expects to be in a position to initiate a Phase 2 study for the treatment of MDD in the fourth quarter of 2021. "We are pleased with the results of the FDA meeting on developing TNX-601 CR for the treatment of MDD and we look forward to advancing its clinical development. Tianeptine products have been approved in Europe and other countries around the world and marketed as prescriptions drugs for treating depression for more than 3 decades. We believe that with respect to tianeptine, TNX-601 CR would meet the bioequivalence standard for daily dosing of these immediate release products. No tianeptine-containing product has been approved by the FDA. TNX-601 CR's proposed mechanism of action is distinct from any approved antidepressant in the U.S," said Seth Lederman, M.D., President and CEO of Tonix Pharmaceuticals.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.39 /

-0.055 (-3.82%)

TNXP Tonix Pharmaceuticals
$1.39 /

-0.055 (-3.82%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.39 /

-0.055 (-3.82%)

TNXP Tonix Pharmaceuticals
$1.39 /

-0.055 (-3.82%)

Hot Stocks
Tonix Pharmaceuticals issued U.S. patent for uses of tianeptine oxalate salt » 07:09
03/19/21
03/19
07:09
03/19/21
07:09
TNXP

Tonix Pharmaceuticals

$1.37 /

-0.125 (-8.36%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,946,027 to the Company on March 16, 2021. Tianeptine oxalate is the active pharmaceutical ingredient of Tonix's development candidate, TNX-601 CR. The new patent, "Tianeptine Oxalate Salts and Polymorphs," includes claims directed to pharmaceutical compositions comprising crystalline tianeptine oxalate salts, to methods of using those compositions to treat various disorders, and to methods of producing the oxalate salts. This patent is expected to provide Tonix with U.S. market exclusivity until December 28, 2037, excluding any patent term extensions. Tonix's TNX-601 CR is a novel oral formulation of one of the claimed tianeptine oxalate salts, which is being developed as a potential treatment for major depressive disorder, posttraumatic stress disorder and neurocognitive dysfunction associated with corticosteroid use. Tianeptine sodium immediate release has been available in Europe for the treatment of depression for more than three decades, first marketed in France in 1989. Tianeptine sodium IR is also marketed in many countries in Asia and Latin America. No tianeptine-containing product has been approved by the U.S. Food and Drug Administration.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.37 /

-0.125 (-8.36%)

TNXP Tonix Pharmaceuticals
$1.37 /

-0.125 (-8.36%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.37 /

-0.125 (-8.36%)

TNXP Tonix Pharmaceuticals
$1.37 /

-0.125 (-8.36%)

On The Fly
Fly Intel: Pre-market Movers » 08:53
03/17/21
03/17
08:53
03/17/21
08:53
IMTX

Immatics

$11.57 /

+0.065 (+0.57%)

, TNXP

Tonix Pharmaceuticals

$1.28 /

-0.045 (-3.41%)

, COHR

Coherent

$248.60 /

+1.18 (+0.48%)

, CRWD

Crowdstrike

$196.30 /

-4.34 (-2.16%)

, MG

Mistras

$10.37 /

-0.35 (-3.26%)

, PDD

Pinduoduo

$160.88 /

+1.84 (+1.16%)

, CTAS

Cintas

$347.64 /

-2.97 (-0.85%)

, KC

Kingsoft Cloud

$50.44 /

+0.26 (+0.52%)

, SRGA

Surgalign

$2.52 /

-0.085 (-3.27%)

, PLUG

Plug Power

$42.71 /

-3.735 (-8.04%)

Check out this morning's…

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

SRGA Surgalign
$2.52 /

-0.085 (-3.27%)

PLUG Plug Power
$42.71 /

-3.735 (-8.04%)

PDD Pinduoduo
$160.88 /

+1.84 (+1.16%)

KC Kingsoft Cloud
$50.44 /

+0.26 (+0.52%)

IMTX Immatics
$11.57 /

+0.065 (+0.57%)

CTAS Cintas
$347.64 /

-2.97 (-0.85%)

CRWD Crowdstrike
$196.30 /

-4.34 (-2.16%)

COHR Coherent
$248.60 /

+1.18 (+0.48%)

IMTX Immatics
$11.57 /

+0.065 (+0.57%)

11/20/20 BofA
Immatics initiated with a Buy at BofA
09/21/20 Goldman Sachs
Immatics initiated with a Buy at Goldman Sachs
07/27/20
Fly Intel: Top five analyst initiations
07/27/20 SVB Leerink
SVB Leerink bullish on Immatics, initiates with an Outperform
TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
COHR Coherent
$248.60 /

+1.18 (+0.48%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
02/08/21 Stifel
Coherent bid may force Lumentum to raise offer, says Stifel
02/08/21 Benchmark
Coherent deal with MKS could face regulators' scrutiny, says Benchmark
CRWD Crowdstrike
$196.30 /

-4.34 (-2.16%)

03/17/21 Jefferies
Crowdstrike FY22 revenue growth guidance 'impressive,' says Jefferies
03/17/21 Needham
Crowdstrike price target raised to $275 from $200 at Needham
03/17/21 DA Davidson
Crowdstrike price target raised to $250 from $185 at DA Davidson
03/17/21 Oppenheimer
Crowdstrike price target raised to $225 from $190 at Oppenheimer
MG Mistras
$10.37 /

-0.35 (-3.26%)

07/10/20 Sidoti
Mistras re-initiated with a Buy at Sidoti
05/12/20 Maxim
Mistras downgraded to Hold from Buy at Maxim
05/12/20 Maxim
Mistras downgraded to Hold from Buy at Maxim
PDD Pinduoduo
$160.88 /

+1.84 (+1.16%)

02/04/21 OTR Global
Pinduoduo vendors' sales growth accelerated through Q4, says OTR Global
01/27/21 Oppenheimer
Pinduoduo price target raised to $200 from $150 at Oppenheimer
01/26/21
Fly Intel: Top five analyst downgrades
01/26/21 KeyBanc
Pinduoduo downgraded to Sector Weight at KeyBanc on balanced risk/reward
CTAS Cintas
$347.64 /

-2.97 (-0.85%)

02/16/21 William Blair
Cintas upgraded to Outperform from Market Perform at William Blair
01/06/21
Fly Intel: Top five analyst upgrades
01/06/21 Morgan Stanley
Morgan Stanley upgrades 'solid compounder' Cintas to Equal Weight
01/06/21 Morgan Stanley
Cintas upgraded to Equal Weight from Underweight at Morgan Stanley
KC Kingsoft Cloud
$50.44 /

+0.26 (+0.52%)

01/05/21
Fly Intel: Top five analyst initiations
01/05/21 Jefferies
Kingsoft Cloud initiated with a Buy at Jefferies
11/03/20 CLSA
Kingsoft Cloud initiated with a Buy at CLSA
06/29/20 Goldman Sachs
Kingsoft Cloud initiated with a Buy at Goldman Sachs
SRGA Surgalign
$2.52 /

-0.085 (-3.27%)

02/03/21
Fly Intel: Top five analyst initiations
02/03/21 BTIG
Surgalign initiated with a Buy at BTIG
02/02/21 Piper Sandler
Surgalign initiated with an Overweight at Piper Sandler
11/30/20
Fly Intel: Top five analyst initiations
PLUG Plug Power
$42.71 /

-3.735 (-8.04%)

03/17/21 B. Riley
Plug Power selloff on 'accounting noise' buying opportunity, says B. Riley
03/17/21 Cowen
Plug Power shares oversold on true accounting error, says Cowen
03/17/21 Cowen
Plug Power weakness 'a unique buying opportunity,' says Cowen
03/17/21 Truist
Plug Power downgraded to Hold from Buy at Truist
TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

SRGA Surgalign
$2.52 /

-0.085 (-3.27%)

PLUG Plug Power
$42.71 /

-3.735 (-8.04%)

PDD Pinduoduo
$160.88 /

+1.84 (+1.16%)

MG Mistras
$10.37 /

-0.35 (-3.26%)

KC Kingsoft Cloud
$50.44 /

+0.26 (+0.52%)

IMTX Immatics
$11.57 /

+0.065 (+0.57%)

CTAS Cintas
$347.64 /

-2.97 (-0.85%)

CRWD Crowdstrike
$196.30 /

-4.34 (-2.16%)

COHR Coherent
$248.60 /

+1.18 (+0.48%)

  • 27
    Jan
  • 28
    Jan
  • 18
    Nov
  • 17
    Nov
  • 24
    Sep
  • 12
    Aug
  • 26
    Jun
  • 08
    May
PLUG Plug Power
$42.71 /

-3.735 (-8.04%)

PDD Pinduoduo
$160.88 /

+1.84 (+1.16%)

CRWD Crowdstrike
$196.30 /

-4.34 (-2.16%)

COHR Coherent
$248.60 /

+1.18 (+0.48%)

TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

PLUG Plug Power
$42.71 /

-3.735 (-8.04%)

PDD Pinduoduo
$160.88 /

+1.84 (+1.16%)

KC Kingsoft Cloud
$50.44 /

+0.26 (+0.52%)

CTAS Cintas
$347.64 /

-2.97 (-0.85%)

CRWD Crowdstrike
$196.30 /

-4.34 (-2.16%)

COHR Coherent
$248.60 /

+1.18 (+0.48%)

PLUG Plug Power
$42.71 /

-3.735 (-8.04%)

PDD Pinduoduo
$160.88 /

+1.84 (+1.16%)

KC Kingsoft Cloud
$50.44 /

+0.26 (+0.52%)

CRWD Crowdstrike
$196.30 /

-4.34 (-2.16%)

Hot Stocks
Tonix Pharmaceuticals reports COVID-19 vaccine efficacy results » 07:04
03/17/21
03/17
07:04
03/17/21
07:04
TNXP

Tonix Pharmaceuticals

$1.28 /

-0.045 (-3.41%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding announced preliminary results following vaccination of non-human primates with TNX-1800, a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 spike protein. Immunogenicity and protective efficacy of single-dose TNX-1800 were assessed at two dose levels. At Day 41 after the vaccination, animals were challenged with live SARS-CoV-2 through intra-nasal and intra-tracheal routes. Protection was assessed at Day 47, six days after challenge. The research is part of an ongoing collaboration between Southern Research, the University of Alberta and Tonix. The Company believes the findings also demonstrate the flexibility of the horsepox vaccine platform and its capability to be tailored to other diseases of interest in military and civilian populations. Key features and results: STUDY DESIGN: This study of non-human primates compared TNX-1800 to TNX-801 at two doses. Also a control group received a placebo. Each of these five groups included four animals. CoV-2 CHALLENGE: At day 41 after vaccination, each animal was exposed to SARS-COV-2 by intra-tracheal and intra-nasal administration. DETECTION OF SARS-COV-2 in Upper and Lower Airway: Upper airway virus was studied by oropharyngeal swabs and lower airway virus by tracheal lavage using qRT-PCR to determine the number of genome copies of SARS-CoV-2 present in the samples. Six days after challenge, no samples taken from animals vaccinated with TNX-1800 showed infection in either upper or lower airway samples. In contrast, all animals vaccinated with the control vaccine TNX-801 showed infection in either the upper or lower airway samples as did all monkeys vaccinated with vehicle control. NEUTRALIZING ANTI-CoV-2 ANTIBODIES: At day 14 after a single vaccination, all eight of the TNX-1800 vaccinated animals made anti-CoV-2 neutralizing antibodies and, as expected, none of the eight TNX-801 vaccinated control animals, or any of the four animals in the placebo group made anti-CoV-2 neutralizing antibodies. At 6 days after CoV-2 challenge, TNX-1800 vaccinated animals showed neutralizing antibody titers of. The level of neutralizing anti-CoV-2 antibody production was similar between the low and high dose TNX-1800 groups. For unvaccinated animals challenged with SARS-CoV-2, neutralizing antibodies were measurable after vaccination that were lower and appeared later than neutralizing antibodies in TNX-1800 vaccinated animals.TOLERABILITY: TNX-1800 and TNX-801 were well tolerated at both doses. SKIN TAKE BIOMARKER: Further, as an expected additional outcome, all 16 animals vaccinated with either dose of TNX-1800 or the control TNX-801 manifested a "take", or cutaneous response, signaling that the horsepox vector elicits a strong T cell immune response. DOSE: These results support the expectation that TNX-1800 at the low dose of 1 x 106 PFU is an appropriate dose for a one-shot vaccine in humans and indicate that 100 doses per vial is the target format for commercialization, which is well suited to manufacturing and distribution at large scale. CONCLUSIONS: Together, these data show that TNX-1800 induces protection against SARS-COV-2 infection in non-human primates. These data confirm that "take" is a biomarker of protection of upper and lower airways from SARS-CoV-2 challenge, and a biomarker of immunological response to TNX-1800's cargo COVID-19 antigen, which is the CoV-2 spike protein. NEXT PHASE: Phase 1 human study targeted to start in the second half of 2021, following Investigational New Drug clearance by the U.S. Food and Drug Administration and the production of GMP material.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

TNXP Tonix Pharmaceuticals
$1.28 /

-0.045 (-3.41%)

Earnings
Tonix Pharmaceuticals reports Q4 EPS (10c), consensus (7c) » 16:47
03/15/21
03/15
16:47
03/15/21
16:47
TNXP

Tonix Pharmaceuticals

$1.32 /

+0.065 (+5.18%)

As of December 31, 2020,…

As of December 31, 2020, Tonix had $77.1M of cash and cash equivalents, compared to $11.2M as of December 31, 2019. Cash used in operations was approximately $48.6M for the full year ended December 31, 2020, compared to $26.7M for full year ended December 31, 2019. The increase in cash used in operations resulted principally from an increase in research and development and general and administrative activities.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.32 /

+0.065 (+5.18%)

TNXP Tonix Pharmaceuticals
$1.32 /

+0.065 (+5.18%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.32 /

+0.065 (+5.18%)

Hot Stocks
Tonix Pharmaceuticals achieves 50% enrollment in RALLY Phase 3 study » 07:10
03/15/21
03/15
07:10
03/15/21
07:10
TNXP

Tonix Pharmaceuticals

$1.26 /

+0.06 (+5.02%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding announced that 50 percent of the planned total number of participants have been randomized in the Phase 3 RALLY study for the management of fibromyalgia. RALLY is the Company's second of two potential pivotal Phase 3 studies of TNX-102 SL 5.6 mg, a non-opioid, centrally acting analgesic, taken daily at bedtime. The RALLY study utilizes the same protocol design as the Company's first positive Phase 3 study, RELIEF, but with an additional 200 patients. "We believe that achieving this milestone keeps us on plan for the anticipated release of interim results from RALLY in the third quarter and topline data in the fourth quarter of this year," said Tonix's President and Chief Executive Officer, Seth Lederman, M.D. "If the topline results are positive, we expect to be in a position to submit a New Drug Application (NDA) for TNX-102 SL for fibromyalgia to the U.S. Food and Drug Administration in 2022." In December 2020, the company reported positive topline results from the RELIEF study, its first Phase 3 study for TNX-102 SL 5.6 mg in fibromyalgia. In the RELIEF study, the 5.6 mg dose achieved statistically significant pain reduction over placebo at Week 14 (primary endpoint, p=0.01). In addition, TNX-102 SL was generally well tolerated with an adverse event profile comparable to prior studies, and no new safety signals observed. An interim analysis of the first 50 percent of randomized participants in the RALLY study will be conducted shortly after the 14-week treatment period has been completed by these participants. Pending approval of the interim statistical analysis plan by the FDA, results from the interim analysis are expected in the third quarter of 2021. The interim analysis will be conducted by an Independent Data Monitoring Committee which will review the unblinded data and make one of four recommendations: (1) stop the study for success; (2) continue to enroll the full study as planned; (3) continue to enroll with a specified increase in the total number of participants in the full study; or (4) stop the study for futility.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.26 /

+0.06 (+5.02%)

TNXP Tonix Pharmaceuticals
$1.26 /

+0.06 (+5.02%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.26 /

+0.06 (+5.02%)

Over a month ago
Hot Stocks
Tonix Pharmaceuticals regains compliance with Nasdaq minimum price rule » 07:44
03/04/21
03/04
07:44
03/04/21
07:44
TNXP

Tonix Pharmaceuticals

$1.12 /

-0.09 (-7.44%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market. On March 3, 2021, Tonix received a letter from The Nasdaq Stock Market LLC stating that because Tonix's shares had a closing bid price at or above $1.00 per share for a minimum of 20 consecutive business days, Tonix's stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1), and the matter is now closed.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.12 /

-0.09 (-7.44%)

TNXP Tonix Pharmaceuticals
$1.12 /

-0.09 (-7.44%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.12 /

-0.09 (-7.44%)

Recommendations
Tonix price target raised to $4 from $3 at Alliance Global Partners » 07:13
02/25/21
02/25
07:13
02/25/21
07:13
TNXP

Tonix Pharmaceuticals

$1.26 /

+0.03 (+2.44%)

Alliance Global Partners…

Alliance Global Partners analyst James Molloy raised the firm's price target on Tonix Pharmaceuticals to $4 from $3 and reiterates a Buy rating on the shares. The company continues to expand its pipeline in the COVID space, Molloy tells investors in a research note.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.26 /

+0.03 (+2.44%)

TNXP Tonix Pharmaceuticals
$1.26 /

+0.03 (+2.44%)

12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.26 /

+0.03 (+2.44%)

Hot Stocks
Tonix licenses technology for treatment of Prader-Willi syndrome » 07:13
02/11/21
02/11
07:13
02/11/21
07:13
TNXP

Tonix Pharmaceuticals

$1.61 /

+0.01 (+0.63%)

Tonix Pharmaceuticals…

Tonix Pharmaceuticals Holding announced an agreement whereby Tonix has licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm. The licensing agreement has been negotiated and signed by Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research), Aix-Marseille Universite and Centre Hospitalier Universitaire of Toulouse. The co-exclusive license allows Tonix to expand its intranasal potentiated oxytocin development program to a new indication. The new program at Tonix has the designation TNX-2900 for the treatment of Prader-Willi syndrome. The patents covering the technology are expected to provide market exclusivity for the co-licensees in the U.S. and Europe through 2031, which exclusivity could be extended after marketing authorization by a Supplemental Protection Certificate in Europe or a Patent Term Extension in the U.S., independent of other Tonix-held patents covering the formulation and oxytocin potentiation technologies for intranasal administration.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.61 /

+0.01 (+0.63%)

TNXP Tonix Pharmaceuticals
$1.61 /

+0.01 (+0.63%)

12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
$1.61 /

+0.01 (+0.63%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.